Company News 

Indivior’s patent conundrum sparks another sell-off

Indivior’s patent conundrum sparks another sell-off

Pharma investors fear the day a company's top-selling drug faces competition for the first time. At Indivior (INDV), that day is approaching worrying quickly. US drugs regulators have granted approval to two unbranded versions of the group’s opioid dependence remedy, Suboxone, sparking fresh concerns that it might face generic competition to its biggest product before its new release, Sublocade, has had time to generate sales momentum.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now